Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia

Table 5

Plasma concentrations of Apo-B-containing lipoprotein particles (mg/dL) in patients with various degrees of chronic renal insufficiency (mild; n = 7, moderate; 𝑛=8, severe; 𝑛=8) and healthy reference subjects (n = 17) at start and end of treatment with 1 mg tesaglitazar o.d. Mean and standard deviation (in parenthesis).

	At entry	After 6 weeks	At entry	After 6 weeks
	Lp-B		Lp-B : C
Reference group	67 (12)	58 (10)	6 (2)	5 (2)
Mild CRF	66 (9)	59 (13)	6 (1)	7 (2)
Moderate CRF	85 (21)	70 (22)	9 (5)	6 (2)
Severe CRF	86 (17)	70 (20)	15 (12)	8 (4)
	Lp-B : E + Lp-B : C : E		Lp-A-II : B : C : D : E
Reference group	13 (6)	10 (4)	20 (9)	15 (8)
Mild CRF	14 (5)	15 (3)	16 (6)	9 (3)
Moderate CRF	22 (7)	14 (5)	17 (6)	17 (7)
Severe CRF	24 (9)	14 (10)	16 (9)	20 (10)